Omicron News and Research

RSS

Symptomatic COVID-19 is associated with deficits in task-related cognitive function and psychiatric symptoms

Researchers conducted a prospective population survey, functional brain imaging, and a cognitive task performance test to determine whether a history of symptomatic coronavirus disease 2019 (COVID-19) was associated with psychiatric and neurocognitive symptoms.

7 Mar 2023

Effectiveness of monovalent COVID-19 mRNA booster vaccination vs. two-dose primary series during Omicron variant circulation

Researchers estimated the immune protection conferred by monovalent-type COVID-19 mRNA booster doses vs. two-dose prime vaccination series during SARS-CoV-2 Omicron variant predominance in community settings.

7 Mar 2023

Antibody levels from prime COVID-19 mRNA vaccine influences the efficacy of booster doses

Researchers evaluate the response of pre-existing immunity to booster doses of mRNA COVID-19 vaccines.

6 Mar 2023

Cirrhosis associated with lower immune responses to COVID-19 vaccines in patients with chronic liver disease

The overall responsiveness of patients with chronic liver disease (CLD) to COVID-19 vaccines has been shown to be decreased in patients with cirrhosis.

2 Mar 2023

SARS-CoV-2 BA.1 and BA.2 breakthrough infections likely protect against BA.4 infection

Omicron BTIs induce durable neutralizing immune responses by recalling cross-reactive and vaccine-induced memory B lymphocytes.

1 Mar 2023

Covid-19 vaccination can curb the effect of long COVID on patients' social, professional, and family lives

Vaccination against SARS-CoV-2, the virus responsible for COVID-19, may lessen the severity and duration of 'long COVID' in those with persistent symptoms after infection, suggests a study that closely imitates a randomized clinical trial, and published in the open access journal, BMJ Medicine.

1 Mar 2023

The effects of Omicron emergence on seroprevalence and hybrid immunity in the Finnish adult population

Researchers evaluated SARS-CoV-2 seroprevalence and population-level humoral immunity among Finnish individuals between April 2020 and December 2022.

28 Feb 2023

Study finds celebrity tweets likely shaped US negative public opinion of COVID-19 pandemic

Researchers evaluated the influence of celebrities on public attitudes toward the COVID-19 pandemic.

28 Feb 2023

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

Researchers evaluate the efficacy of ivermectin in a maximum dosage of 600 μg/kg/day over six days in treating early mild-to-moderate COVID-19.

27 Feb 2023

Study shows COVID-19 rates were likely forty-times higher than CDC estimates during BA.4/BA.5 dominant period in the U.S.

Researchers evaluate the prevalence of SARS-CoV-2 infections and the incidence of long COVID during BA.4/BA.5 dominant period.

27 Feb 2023

Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?

Researchers compared the efficacy of a third COVID-19 vaccine dose and that of homologous and heterologous regimens.

23 Feb 2023

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

23 Feb 2023

Study shows antibody-dependent SARS-CoV-2 transmission and pathogenesis

Researchers reported that some monoclonal nAbs directed against distinct RBD epitopes nested inside the SARS-CoV-2 S could substitute ACE2 as a receptor and support fusion between viral and host cell membranes facilitating viral infectivity.

23 Feb 2023

CDC evaluation of the efficacy of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection in 3 to 5-year-olds

The complete primary series monovalent mRNA vaccines protect children aged three to five against symptomatic infection for up to four months.

22 Feb 2023

RBD-NTD-subunit protein vaccine provides a promising booster vaccination strategy capable of protecting against known SARS-CoV-2 variants

Researchers assessed the impact of SARS-CoV-2 spike NTD incorporation into the RBD protein vaccine.

22 Feb 2023

New analysis shows how convalescent plasma can be used as effective, low-cost COVID-19 treatment

Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe.

22 Feb 2023

MHRA authorizes new version of the Moderna ‘bivalent’ Covid vaccine

Authorization has today been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for a new version of the Moderna 'bivalent' Covid vaccine (Spikevax) that targets both the original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 sub-variants.

21 Feb 2023

Prior COVID highly protective against severe disease ten months post-infection

In a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history.

19 Feb 2023

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

In a recent study published in the journal Eurosurveillance, researchers investigated whether prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) vaccination protected against SARS-CoV-2 Omicron variant of concern (VOC) BA.4/5 sub-VOC or BA.2 sub-VOC infections.

19 Feb 2023

How effective has the bivalent booster COVID vaccination been?

In a recent study published in the journal Eurosurveillance, researchers estimated the effectiveness of bivalent messenger ribonucleic acid (mRNA) vaccines targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 subvariant and the original Wuhan-Hu1 strain against Omicron infections in the vaccinated population of the Netherlands between 26 September and 19 December 2022.

19 Feb 2023

Omicron News and Research

Symptomatic COVID-19 is associated with deficits in task-related cognitive function and psychiatric symptoms

Effectiveness of monovalent COVID-19 mRNA booster vaccination vs. two-dose primary series during Omicron variant circulation

Antibody levels from prime COVID-19 mRNA vaccine influences the efficacy of booster doses

Cirrhosis associated with lower immune responses to COVID-19 vaccines in patients with chronic liver disease

SARS-CoV-2 BA.1 and BA.2 breakthrough infections likely protect against BA.4 infection

Covid-19 vaccination can curb the effect of long COVID on patients' social, professional, and family lives

The effects of Omicron emergence on seroprevalence and hybrid immunity in the Finnish adult population

Study finds celebrity tweets likely shaped US negative public opinion of COVID-19 pandemic

High-dose ivermectin does not reduce COVID-19 symptom duration among mild-to-moderate outpatients

Study shows COVID-19 rates were likely forty-times higher than CDC estimates during BA.4/BA.5 dominant period in the U.S.

Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Study shows antibody-dependent SARS-CoV-2 transmission and pathogenesis

CDC evaluation of the efficacy of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection in 3 to 5-year-olds

RBD-NTD-subunit protein vaccine provides a promising booster vaccination strategy capable of protecting against known SARS-CoV-2 variants

New analysis shows how convalescent plasma can be used as effective, low-cost COVID-19 treatment

MHRA authorizes new version of the Moderna ‘bivalent’ Covid vaccine

Prior COVID highly protective against severe disease ten months post-infection

After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2

How effective has the bivalent booster COVID vaccination been?

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News